Efficacy And Safety Of Ritlecitinib In Alopecia Areata: A Systematic Review And Meta-Analysis

This systematic review and meta-analysis evaluated the efficacy and safety of ritlecitinib in treating alopecia areata, including 4 studies with a total of 411 patients. The analysis found that ritlecitinib significantly improved hair regrowth compared to placebo, with a mean difference in SALT scores of 30.58 (P < 0.00001). Although the drug shows promise as an effective treatment targeting the disease's complex pathophysiology, further research is necessary to fully understand its potential through additional clinical and translational studies. The pooled risk ratio for adverse events was 1.27, indicating no significant increase in risk compared to placebo.